anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Opioid use disorder (OUD) remains a significant public health challenge with high recurrence rates and varied long-term outcomes. Affective temperament and emotion regulation have been identified as influencing addictive behaviors and treatment outcomes in OUD. However, limited research has explored their association with reversion over an extended period.
OBJECTIVES: The EDATOUD (Emotion Dysregulation and Affective Temperaments in Opioid Use Disorder) study aimed to evaluate the effects of affective temperament and emotion regulation characteristics on recurrence over a 1-year follow-up period. The study aimed to compare the baseline characteristics of patients who achieved remission versus those who did not and identify potential predictors of recurrence risk.
METHODS: The study included 63 patients with OUD who were assessed monthly for return-to-use through self-report, psychiatric examination, and urine analysis. Sociodemographic data, affective temperament, difficulties in emotion regulation, anxiety, and depression were measured at baseline. Statistical analyses were performed to compare the recurrent and remission groups and determine the predictive value of these clinical features on recurrence.
RESULTS: Within the one-year, 77.8% of patients returned to use. Affective temperament characteristics did not differ between the groups. However, the recurrent group patients exhibited significantly more difficulties in emotion regulation.
CONCLUSIONS: Difficulties in emotion regulation are associated with an increased risk of recurrence in patients with OUD. Understanding these factors can inform the development of tailored treatment strategies to improve long-term outcomes. Further research is needed to explore additional factors contributing to reversion and enhance intervention and support systems for sustained recovery in OUD.
FIELD: medicine.SUBSTANCE: invention relates to medicine and is intended to optimize the treatment of stromal tumors of the gastrointestinal tract with imatinib. The method involves the introduction of a predetermined fixed amount of imatinib mesylate in a daily dose of 400 mg. Blood sampling is carried out after the first 30 days of treatment. The minimum level of imatinib in blood plasma is determined by high-performance liquid chromatography and tandem mass spectrometry. Identification of the values at which an adjustment of the dose of imatinib mesilate is necessary, repeated control determination of the drug concentration in the blood serum 30 days after the adjustment. If the level of imatinib is detected within 500-899 ng/ml, the daily dose is increased by 200 mg, if the level of imatinib is detected below 500 ng/ ml, the daily dose is increased by 400 mg, if the level of imatinib is detected above 1500 ng/ml, the daily dose is reduced by 200 mg, and if the level of imatinib is detected within 900-1500 ng/ml, treatment is continued at the previous daily dose.EFFECT: invention makes it possible to change the daily dose of imatinib in a timely manner based on data on the concentration of the drug in the plasma of patients and to increase the effectiveness of treatment and the quality of life due to an individual approach to the treatment of this group of patients.1 cl. 1 ex, 1 tbl
BREYNA

BREYNA contains both budesonide and formoterol fumarate dihydrate; therefore, the risks associated with overdosage for the individual components described below apply to BREYNA. In pharmacokinetic studies, single doses of 960/54 mcg (12 actuations of budesonide and formoterol fumarate dihydrate inhalation aerosol 80 mcg/4.5 mcg) and 1280/36 mcg (8 actuations of 160 mcg/4.5 mcg), were administered to patients with COPD. A total of 1920/54 mcg (12 actuations of budesonide and formoterol fumarate dihydrate inhalation aerosol 160 mcg/4.5 mcg) was administered as a single dose to both healthy subjects and patients with asthma. In a long-term active-controlled safety study in adolescent and adult asthma patients 12 years of age and older, budesonide and formoterol fumarate dihydrate inhalation aerosol 160 mcg/4.5 mcg was administered for up to 12 months at doses up to twice the highest recommended daily dose. There were no clinically significant adverse reactions observed in any of these studies.

Budesonide

The potential for acute toxic effects following overdose of budesonide is low. If used at excessive doses for prolonged periods, systemic corticosteroid effects such as hypercorticism may occur [see Warnings and Precautions (5)]. Budesonide at five times the highest recommended dose (3200 mcg daily) administered to humans for 6 weeks caused a significant reduction (27%) in the plasma cortisol response to a 6-hour infusion of ACTH compared with placebo (+1%). The corresponding effect of 10 mg prednisone daily was a 35% reduction in the plasma cortisol response to ACTH.

Formoterol

An overdose of formoterol would likely lead to an exaggeration of effects that are typical for beta2‑agonists: seizures, angina, hypertension, hypotension, tachycardia, atrial and ventricular tachyarrhythmias, nervousness, headache, tremor, palpitations, muscle cramps, nausea, dizziness, sleep disturbances, metabolic acidosis, hyperglycemia, hypokalemia. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of formoterol. No clinically significant adverse reactions were seen when formoterol was delivered to adult patients with acute bronchoconstriction at a dose of 90 mcg/day over 3 hours or to stable asthmatics 3 times a day at a total dose of 54 mcg/day for 3 days.

Treatment of formoterol overdosage consists of discontinuation of the medication together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of formoterol. Cardiac monitoring is recommended in cases of overdosage.
INTRODUCTION: Tauopathies are a spectrum of clinicopathological neurodegenerative disorders with increased aggregates included in glia and/or neurons of hyperphosphorylated insoluble tau protein, a microtubule-associated protein. Progressive supranuclear palsy (PSP) is an atypical dopaminergic-resistant parkinsonian syndrome, considered as a primary tauopathy with possible alteration of tau isoform ratio, and tau accumulations characterized by 4 R tau species as the main neuropathological lesions.
AREAS COVERED: In the present review article, we analyzed and discussed viable disease-modifying and some symptomatic pharmacological therapeutics for PSP syndrome (PSPS).
EXPERT OPINION: Pharmacological therapy for PSPS may interfere with the aggregation process or promote the clearance of abnormal tau aggregates. A variety of past and ongoing disease-modifying therapies targeting tau in PSPS included genetic, microtubule-stabilizing compounds, anti-phosphorylation, and acetylation agents, antiaggregant, protein removal, antioxidant neuronal and synaptic growth promotion therapies. New pharmacological gene-based approaches may open alternative prevention pathways for the deposition of abnormal tau in PSPS such as antisense oligonucleotide (ASO)-based drugs. Moreover, kinases and ubiquitin-proteasome systems could also be viable targets.
Single weight-based IV administration of P-BCMA-ALLO1. Rimiducid may be administered as indicated.
Patients using clotrimazole and betamethasone dipropionate lotion should receive the following information and instructions:

  1. The medication is to be used as directed by the physician and is not recommended for use longer than the prescribed time period. It is for external use only. Avoid contact with the eyes, the mouth, or intravaginally.
  2. This medication is to be used for the full prescribed treatment time, even though the symptoms may have improved. Notify the physician if there is no improvement after 1 week of treatment for tinea cruris or tinea corporis, or after 2 weeks for tinea pedis.
  3. This medication should only be used for the disorder for which it was prescribed.
  4. Other corticosteroid-containing products should not be used with clotrimazole and betamethasone dipropionate without first talking with your physician.
  5. The treated skin area should not be bandaged, covered, or wrapped so as to be occluded (see DOSAGE AND ADMINISTRATION).
  6. Any signs of local adverse reactions should be reported to your physician.
  7. Patients should avoid sources of infection or reinfection.
  8. When using clotrimazole and betamethasone dipropionate lotion in the groin area, patients should use the medication for 2 weeks only, and apply the lotion sparingly. Patients should wear loose-fitting clothing. Notify the physician if the condition persists after 2 weeks.
  9. The safety of clotrimazole and betamethasone dipropionate lotion has not been demonstrated in the treatment of diaper dermatitis. The use of clotrimazole and betamethasone dipropionate lotion in the treatment of diaper dermatitis is not recommended.
BACKGROUND: Thoracoabdominal normothermic regional perfusion (TA-NRP) has been increasingly used for donation after circulatory death (DCD) procurements in the United States. We present the largest report of outcomes of kidney transplants performed using DCD donor grafts perfused with TA-NRP.
METHODS: Adult DCD kidney transplants between 2020 and 2022 in the United Network for Organ Sharing database were included. Donors with ≥50 min between asystole and aortic cross-clamp time in which the heart was also transplanted were considered TA-NRP donors. All other donors were considered direct recovery donors. Multivariable regressions were used to assess delayed graft function, as well as posttransplant survival and all-cause graft failure at 30, 90, and 180 d. A propensity-matched analysis of cohorts matched on donor Kidney Donor Profile Index was performed.
RESULTS: Of the 16 140 total DCD kidney transplants performed during the study period, 306 (1.9%) used TA-NRP. TA-NRP donors were younger ( P  < 0.001) and had lower Kidney Donor Profile Index ( P  < 0.001) compared with direct recovery donors. Recipients receiving grafts recovered using TA-NRP were younger ( P  < 0.001) and more likely to be blood group O ( P  < 0.001). Transplants using TA-NRP had lower likelihood of delayed graft function (adjusted odds ratio 0.22 [95% confidence interval, 0.15-0.31], P  < 0.001) but similar 180-d survival ( P  = 0.8) and all-cause graft failure ( P  = 0.3) as transplants using direct recovery grafts. These inferences were unchanged on propensity-matched analysis.
CONCLUSIONS: Our results demonstrate that kidney transplants using TA-NRP DCD allografts have positive short-term mortality and graft survival outcomes, with significantly decreased rates of delayed graft function compared with direct recovery DCD grafts.
Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
Certain embodiments present a system for navigating medical images of a patient file stored in an image database. An image labeler labels medical images based upon whether the images have previously been displayed on an interface. The system also provides an image search engine that searches the images based on the labels. The image search engine generates a subset of images from a larger group of medical images within a database based upon the labels. The interface includes a graphical meter that corresponds to medical images that have not previously been displayed on the interface. The graphical meter may enumerate the quantity of images that have not previously been displayed. The graphical meter may also illustrate the proportion of images that have not previously been displayed. The graphical meter may include a hyperlink that points to an image that has not previously been displayed. The graphical meter may also include a hyperlink that points to a location containing the images that have not been previously displayed.
Concomitant use of BREVIBLOC injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate BREVIBLOC's effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and monoxide below.) BREVIBLOC should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to:

  * Digitalis glycosides: Concomitant administration of digoxin and BREVIBLOC leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect BREVIBLOC pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease the heart rate. Concomitant use increases the risk of bradycardia.
  * Anticholinesterases: BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.
  * Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.
  * Calcium channel antagonists: In patients with depressed myocardial function, use of BREVIBLOC with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.
  * Sympathomimetic drugs: Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of BREVIBLOC.
  * Vasoconstrictive and positive inotropic agents: Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance, do not use BREVIBLOC to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine.
The invention discloses a 3, 4-fused seven-membered heterocyclic oxindole oxide structure with bioactivity, and a synthesis method and application thereof. The invention provides a structure of a 3, 4-position fused seven-membered nitrogen heterocycle oxindole bioactive skeleton. The invention provides a synthesis method thereof, which comprises the following steps: propargyl alcohol containing an isatin skeleton reacts with a nucleophilic reagent under certain conditions to prepare the oxindole oxide compound of the 3, 4-position thick seven-membered nitrogen heterocycle. The invention provides a pharmaceutical composition. The invention also provides application of the 3, 4-position fused seven-membered nitrogen heterocycle oxindole bioactive skeleton in preparing medicaments for treating cancers and the like. The method for efficiently synthesizing the oxindole compounds with diversified 3, 4-position thick seven-membered nitrogen heterocycles has the advantage that the bioactive molecules containing two structures of benzazepine and 3, 4-position thick heteroauxin are efficiently synthesized based on a hydrogen migration strategy for the first time.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to method of treatment and prophylaxis of bone thinning in patients by administration of alendronate liquid composition that can be swallowed easily. Invention describes also pharmaceutical dosed forms of alendronate as syrup, an aqueous solution or solution prepared by power dissolving to realize the therapeutical method described. These compositions can be administrated in patients having difficulty in swallowing. EFFECT: improved medicinal form and stability of drug. 25 cl, 3 ex
Schools will have take home saliva kits available at the school to support SARS-CoV-2 diagnostic testing. Schools will transition to the intervention phase at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study.
The invention relates the technical field of biological and traditional Chinese medicine skin-cleaning cosmetics and especially relates to a skin-cleaning agent composition adopting gelatin as a main material and a preparation method thereof. The skin-cleaning agent composition comprises gelatin as a main material, and defatted soybean protein powder and sodium alginate as auxiliary materials, wherein the gelatin has molecular mass of 30000 to 100000 and is refined from animal skin, bones, shells and horns. Concretely, the skin-cleaning agent composition comprises 0.5 to 100% of skin-gelatin, 0.5 to 100% of bone gelatin (having molecular mass of 30000 to 100000), 0.5 to 10% of donkey-hide gelatin, 0.2 to 15% of tortoise-plastron glue, 1 to 15% of turtle shell glue, 0.3 to 10% of deer-horn glue, 5 to 25% of a defatted soybean protein and 0.5 to 15% of sodium alginate. The raw materials satisfy the national food-grade or medicine-grade production standard. The preparation method comprises the following steps of crushing various types of gelatin into powder having particle sizes of 60 to 100 meshes by professional gelatin processing equipment and mixing the powder and other materials to form an end product. The skin-cleaning agent composition is mainly used for face washing and water bath. Compared with the traditional chemical skin-cleaning products, the skin-cleaning agent composition is natural, environmentally friendly and healthy, and has low carbon content, good health care effects, good safety and good reliability. The skin-cleaning agent composition is suitable for pregnant women and children.
The invention discloses health-care medicinal liquor for treating high blood pressure as well as a preparation method thereof. The health-care medicinal liquor comprises 1800g of yellow rice wine, Chinese herbal medicines and auxiliary materials. The health-care medicinal liquor comprises the following Chinese herbal medicines by weight: 10g of lumbricus, 5g of semen plantaginis, 15g of Concha Margaritiferallsta, 16g of selfheal, 13g of ruddle, 20g of Chinese yam, 10g of membrane of gizzard, 15g of sticktight, 10g of glossy privet fruits, 12g of Schisandra chinensis, 10g of medlar, 18g of crude malt, 15g of corn stigma, 12g of crude liquorice and 15g of gastrodia elata. According to the health-care medicinal liquor, no pigments, additives, chemical components and mineral substances are added in the production process. All substances in a prescription are natural Chinese herbal medicines. The processing method is simple to operate, and the medicinal materials used are easy to get. The health-care medicinal liquor is low in cost, remarkable in curative effect, hardly causes side effects, and has a good preventing and treating effect on high blood pressure.
The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).